biosimilars

R&D

Sandoz’s Pierre Bourdage on biosimilars: the pharmaphorum po...

In the latest episode of the podcast Dominic Tyer speaks with Pierre Bourdage, who’s global head of biopharmaceuticals at Sandoz about the big issues in biosimilars.

News

Alvotech files lawsuit challenging AbbVie's Humira patent th...

Biosimilars firm Alvotech has filed a lawsuit that challenges AbbVie’s legal defences surrounding the inflammatory disease drug Humira in the US.

Views & Analysis

2021 market access prospects for Spain

2021 will be the year when big market access changes – including the far wider use of health economic evaluation – are implemented in Spain.

Views & Analysis

Nine for 2021: Addressing the pandemic legacy

In this second 'Nine for 2021' article, IQVIA’s Sarah Rickwood looks at four issues which will directly impact pharma in 2021: t

News

Novartis set to overcome $14 billion patent cliff say analys...

Novartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition in the coming years, analysts have said.

News

Will Gottlieb follow up on Trump's promise of a bonfire of regulations?

FDA begins review of Samsung Bioepis/Biogen's Lucentis biosi...

Novartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its US patent expired this year – and Samsung Bioepis and Biogen

Sandoz’s Pierre Bourdage on biosimilars: the pharmaphorum po...

Alvotech files lawsuit challenging AbbVie's Humira patent th...

2021 market access prospects for Spain

Nine for 2021: Addressing the pandemic legacy

Novartis set to overcome $14 billion patent cliff say analys...

FDA begins review of Samsung Bioepis/Biogen's Lucentis biosi...

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

biosimilars

Editor's Picks